

INFORMATION DISCLOSURE CITATION*(Use several sheets if necessary)*ATTY. DOCKET NO.
33714-US-PCT
APPLICATION NO.
10/599,697
APPLICANT
WAGNER ET AL.
FILING DATE
OCTOBER 5, 2006Group
1612**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Simulect basiliximab injection powder, for solution, Novartis Pharmaceuticals Corporation, Revised September 2005
	AS	Neoral-cyclosporine capsule, liquid filled, Novartis Pharmaceuticals Corporation, Revised August 2005
	AT	Rapamune (sirolimus) tablet, sugar coated for oral use, Wyeth Pharmaceuticals Inc., Revised July 2008

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.